Factors associated with changes in serum transthyretin after treatment with tafamidis and outcomes in transthyretin cardiac amyloidosis
Amyloid
.
2021 Dec;28(4):267-268.
doi: 10.1080/13506129.2021.1904390.
Epub 2021 Aug 11.
Authors
Sunil E Saith
1
,
Danilo Gamino
1
,
Sergio Teruya
1
,
Samantha Guadalupe
1
,
Stephen Helmke
1
,
Jeffeny De Los Santos
1
,
Jeff Goldsmith
1
,
Hannah R Rosenblum
1
,
Jan M Griffin
1
,
Mathew S Maurer
1
Affiliation
1
Division of Cardiology, Department of Medicine, Columbia University Irving Medical Center, New York, NY, USA.
PMID:
34379010
DOI:
10.1080/13506129.2021.1904390
No abstract available
Publication types
Letter
MeSH terms
Amyloid Neuropathies, Familial* / drug therapy
Amyloid Neuropathies, Familial* / genetics
Benzoxazoles
Humans
Prealbumin* / genetics
Substances
Benzoxazoles
Prealbumin
tafamidis